ILAE clinical practice recommendations for the medical treatment of depression in adults with epilepsy.
depression
epilepsy
treatment
Journal
Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
16
11
2021
received:
19
03
2021
accepted:
19
11
2021
pubmed:
7
12
2021
medline:
21
4
2022
entrez:
6
12
2021
Statut:
ppublish
Résumé
The aim of this document is to provide evidence-based recommendations for the medical treatment of depression in adults with epilepsy. The working group consisted of members of an ad hoc Task Force of the International League Against Epilepsy (ILAE) Commission on Psychiatry, ILAE Executive and the International Bureau for Epilepsy (IBE) representatives. The development of these recommendations is based on a systematic review of studies on the treatment of depression in adults with epilepsy, and a formal adaptation process of existing guidelines and recommendations of treatment of depression outside epilepsy using the ADAPTE process. The systematic review identified 11 studies on drug treatments (788 participants, class of evidence III and IV); 13 studies on psychological treatments (998 participants, class of evidence II, III and IV); and 2 studies comparing sertraline with cognitive behavioral therapy (CBT; 155 participants, class of evidence I and IV). The ADAPTE process identified the World Federation of Societies of Biological Psychiatry guidelines for the biological treatment of unipolar depression as the starting point for the adaptation process. This document focuses on first-line drug treatment, inadequate response to first-line antidepressant treatment, and duration of such treatment and augmentation strategies within the broader context of electroconvulsive therapy, psychological, and other treatments. For mild depressive episodes, psychological interventions are first-line treatments, and where medication is used, selective serotonin reuptake inhibitors (SSRIs) are first-choice medications (Level B). SSRIs remain the first-choice medications (Level B) for moderate to severe depressive episodes; however, in patients who are partially or non-responding to first-line treatment, switching to venlafaxine appears legitimate (Level C). Antidepressant treatment should be maintained for at least 6 months following remission from a first depressive episode but it should be prolonged to 9 months in patients with a history of previous episodes and should continue even longer in severe depression or in cases of residual symptomatology until such symptoms have subsided.
Substances chimiques
Antidepressive Agents
0
Serotonin Uptake Inhibitors
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
316-334Informations de copyright
© 2021 International League Against Epilepsy.
Références
Mula M, Kanner AM, Jette N, Sander JW. Psychiatric comorbidities in people with epilepsy. Neurol Clin Pract. 2021;11(2):e112-20. https://doi.org/10.1212/CPJ.0000000000000874
Fiest KM, Dykeman J, Patten SB, Wiebe S, Kaplan GG, Maxwell CJ, et al. Depression in epilepsy: a systematic review and meta-analysis. Neurology. 2013;80(6):590-9.
Maguire MJ, Weston J, Singh J, Marson AG. Antidepressants for people with epilepsy and depression. Cochrane Database Syst Rev. 2014;12:CD010682.
Kerr MP, Mensah S, Besag F, de Toffol B, Ettinger A, Kanemoto K, et al. International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy. Epilepsia. 2011;52(11):2133-8.
Barry JJ, Ettinger AB, Friel P, Gilliam FG, Harden CL, Hermann B, et al. Consensus statement: the evaluation and treatment of people with epilepsy and affective disorders. Epilepsy Behav. 2008;13(Suppl 1):S1-29.
Kanner AM. Obstacles in the treatment of common psychiatric comorbidities in patients with epilepsy: what is wrong with this picture? Epilepsy Behav. 2019;98(Pt B):291-2.
Sauro KM, Wiebe S, Perucca E, French J, Dunkley C, de Marinis A, et al. Developing clinical practice guidelines for epilepsy: a report from the ILAE epilepsy guidelines working group. Epilepsia. 2015;56(12):1859-69.
Fervers B, Burgers JS, Voellinger R, Brouwers M, Browman GP, Graham ID, et al. Guideline adaptation: an approach to enhance efficiency in guideline development and improve utilisation. BMJ Qual Saf. 2011;20(3):228-36.
Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord. 2000;58(1):19-36.
Mula M, Jauch R, Cavanna A, Collimedaglia L, Barbagli D, Gaus V, et al. Clinical and psychopathological definition of the interictal dysphoric disorder of epilepsy. Epilepsia. 2008;49(4):650-6.
Mula M, Sander JW. Current and emerging drug therapies for the treatment of depression in adults with epilepsy. Expert Opin Pharmacother. 2019;20(1):41-5.
Beck A, Steer R, Brown G. Beck Depression Inventory: Second Edition Manual. The Psychological Corporation; 1996.
Edlund W, Gronseth G, So Y, Franklin G. Clinical Practice Guideline Process Manual. American Academy Neurology; 2004.
Peng W-F, Wang X, Hong Z, Zhu G-X, Li B-M, Li Z, et al. The anti-depression effect of Xylaria nigripes in patients with epilepsy: a multicenter randomized double-blind study. Seizure. 2015;29:26-33.
Zhu S, Luo L, Gui Y. Short term efficacy of venlafaxine treating the depression in epilepsy patients. Chin J Rehabil. 2004;19(2):101.
Kanner AM, Kozak AM, Frey M. The use of sertraline in patients with epilepsy: is it safe? Epilepsy Behav. 2000;1(2):100-5.
Thomé-Souza MS, Kuczynski E, Valente KD. Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy Behav. 2007;10(3):417-25.
Hovorka J, Herman E, Nemcová I. Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy Behav. 2000;1(6):444-7.
Specchio LM, Iudice A, Specchio N, La Neve A, Spinelli A, Galli R, et al. Citalopram as treatment of depression in patients with epilepsy. Clin Neuropharmacol. 2004;27(3):133-6.
Kühn KU, Quednow BB, Thiel M, Falkai P, Maier W, Elger CE. Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy Behav. 2003;4(6):674-9.
Robertson MM, Trimble MR. The treatment of depression in patients with epilepsy. A double-blind trial. J Affect Disord. 1985;9(2):127-36.
Li W, Ma D. A randomized controlled trial to evaluate the efficacy of paroxetine and doxepin in treating epileptic patients with depression. Chin J Clin Rehabil. 2005;9(12):674-9.
Mula M. The pharmacological management of psychiatric comorbidities in patients with epilepsy. Pharmacol Res. 2016;107:147-53.
Gilliam FG, Black KJ, Carter J, Freedland KE, Sheline YI, Tsai W-Y, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Ann Neurol. 2019;86(4):552-60.
McLaughlin DP, McFarland K. A randomized trial of a group based cognitive behavior therapy program for older adults with epilepsy: the impact on seizure frequency, depression and psychosocial well-being. J Behav Med. 2011;34(3):201-7.
Thompson NJ, Patel AH, Selwa LM, Stoll SC, Begley CE, Johnson EK, et al. Expanding the efficacy of Project UPLIFT: distance delivery of mindfulness-based depression prevention to people with epilepsy. J Consult Clin Psychol. 2015;83(2):304-13.
Crail-Melendez D, Herrera-Melo A, Martinez-Juarez IE, Ramirez-Bermudez J. Cognitive-behavioral therapy for depression in patients with temporal lobe epilepsy: a pilot study. Epilepsy Behav. 2012;23:52-6.
Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller H-J, et al. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013;14(5):334-85.
Bandelow B, Zohar J, Kasper S, Möller H-J. How to grade categories of evidence. World J Biol Psychiatry. 2008;9(4):242-7.
Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47-53.
Michaelis R, Tang V, Goldstein LH, Reuber M, LaFrance WC, Lundgren T, et al. Psychological treatments for adults and children with epilepsy: evidence-based recommendations by the international league against epilepsy psychology task force. Epilepsia. 2018;59(7):1282-302.
Christensen J, Vestergaard M, Mortensen PB, Sidenius P, Agerbo E. Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol. 2007;6:693-8.
Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of food and drug administration (FDA) summary basis of approval reports. Biol Psychiatry. 2007;62:345-54.
Dunner DL, Zisook S, Billow AA, Batey SR, Johnston JA, Ascher JA. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry. 1998;59(7):366-73.
Italiano D, Spina E, de Leon J. Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants. Expert Opin Drug Metab Toxicol. 2014;10(11):1457-89.
Kramlinger KG, Post RM. Addition of lithium carbonate to carbamazepine: hematological and thyroid effects. Am J Psychiatry. 1990;147(5):615-20.
Vieweg V, Glick JL, Herring S, Kerler R, Godleski LS, Barber J, et al. Absence of carbamazepine-induced hyponatremia among patients also given lithium. Am J Psychiatry. 1987;144(7):943-7.
Abraham G, Owen J. Topiramate can cause lithium toxicity. J Clin Psychopharmacol. 2004;24:565-7.
Erwin CW, Gerber CJ, Morrison SD, James JF. Lithium carbonate and convulsive disorders. Arch Gen Psychiatry. 1973;28(5):646-8.
Tondo L, Alda M, Bauer M, Bergink V, Grof P, Hajek T, et al. Clinical use of lithium salts: guide for users and prescribers. Int J Bipolar Disord. 2019;7(1):16.
Meltzer HY, Bonaccorso S, Bobo WV, Chen Y, Jayathilake K. A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation. J Clin Psychiatry. 2011;72(12):1602-10.
Biton V. Weight change and antiepileptic drugs: health issues and criteria for appropriate selection of an antiepileptic agent. Neurologist. 2006;12:163-7.
Wu C-S, Wang S-C, Yeh I-J, Liu S-K. Comparative risk of seizure with use of first- and second-generation antipsychotics in patients with schizophrenia and mood disorders. J Clin Psychiatry. 2016;77(5):e573-9.
Ng QX, Venkatanarayanan N, Ho CYX. Clinical use of hypericum perforatum (St John’s wort) in depression: a meta-analysis. J Affect Disord. 2017;210:211-21.
Zhou S, Chan E, Pan S-Q, Huang M, Lee EJD. Pharmacokinetic interactions of drugs with St John’s wort. J Psychopharmacol. 2004;18(2):262-76.
Ivetic V, Trivic S, Pogancev MK, Popovic M, Zlinská J. Effects of St John’s wort (Hypericum perforatum L.) extracts on epileptogenesis. Mol Basel Switz. 2011;16(9):8062-75.
Coffey CE, Lucke J, Weiner RD, Krystal AD, Aque M. Seizure threshold in electroconvulsive therapy (ECT) II. The anticonvulsant effect of ECT. Biol Psychiatry. 1995;37:777-88.
San-Juan D, Dávila-Rodríguez DO, Jiménez CR, González MS, Carranza SM, Hernández Mendoza JR, et al. Neuromodulation techniques for status epilepticus: a review. Brain Stimulat. 2019;12(4):835-44.
Lisanby SH, Maddox JH, Prudic J, Devanand DP, Sackeim HA. The effects of electroconvulsive therapy on memory of autobiographical and public events. Arch Gen Psychiatry. 2000;57(6):581-90.
Baxendale S, O’Sullivan J, Heaney D. Bright light therapy for symptoms of anxiety and depression in focal epilepsy: randomised controlled trial. Br J Psychiatry. 2013;202(5):352-6.
Spindler P, Bohlmann K, Straub H-B, Vajkoczy P, Schneider UC. Effects of vagus nerve stimulation on symptoms of depression in patients with difficult-to-treat epilepsy. Seizure. 2019;69:77-9.
Conway CR, Udaiyar A, Schachter SC. Neurostimulation for depression in epilepsy. Epilepsy Behav. 2018;88S:25-32.
Aaronson ST, Carpenter LL, Conway CR, Reimherr FW, Lisanby SH, Schwartz TL, et al. Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression: acute and chronic effects. Brain Stimulat. 2013;6(4):631-40.
McClintock SM, Reti IM, Carpenter LL, McDonald WM, Dubin M, Taylor SF, et al. Consensus recommendations for the clinical application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression. J Clin Psychiatry. 2018;79(1):35-48.
Lefaucheur J-P, Antal A, Ayache SS, Benninger DH, Brunelin J, Cogiamanian F, et al. Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS). Clin Neurophysiol. 2017;128(1):56-92.
Fregni F, El-Hagrassy MM, Pacheco-Barrios K, Carvalho S, Leite J, Simis M, et al. Evidence-based guidelines and secondary meta-analysis for the use of transcranial direct current stimulation (tDCS) in neurological and psychiatric disorders. Int J Neuropsychopharmacol. 2021;24(4):256-313.
Liu A, Bryant A, Jefferson A, Friedman D, Minhas P, Barnard S, et al. Exploring the efficacy of a 5-day course of transcranial direct current stimulation (TDCS) on depression and memory function in patients with well-controlled temporal lobe epilepsy. Epilepsy Behav. 2016;55:11-20.
Ettinger AB, Kustra RP, Hammer AE. Effect of lamotrigine on depressive symptoms in adult patients with epilepsy. Epilepsy Behav. 2007;10(1):148-54.
Mazza M, Della Marca G, Di Nicola M, Martinotti G, Pozzi G, Janiri L, et al. Oxcarbazepine improves mood in patients with epilepsy. Epilepsy Behav. 2007;10(3):397-401.
Fakhoury TA, Miller JM, Hammer AE, Vuong A. Effects of lamotrigine on mood in older adults with epilepsy and co-morbid depressive symptoms: an open-label, multicentre, prospective study. Drugs Aging. 2008;25(11):955-62.
Fakhoury TA, Barry JJ, Mitchell Miller J, Hammer AE, Vuong A. Lamotrigine in patients with epilepsy and comorbid depressive symptoms. Epilepsy Behav. 2007;10(1):155-62.
Orjuela-Rojas JM, Martínez-Juárez IE, Ruiz-Chow A, Crail-Melendez D. Treatment of depression in patients with temporal lobe epilepsy: a pilot study of cognitive behavioral therapy vs. selective serotonin reuptake inhibitors. Epilepsy Behav. 2015;51:176-81.
Sajatovic M, Tatsuoka C, Welter E, Perzynski AT, Colon-Zimmermann K, Van Doren JR, et al. Targeted self-management of epilepsy and mental illness for individuals with epilepsy and psychiatric comorbidity. Epilepsy Behav. 2016;64(Pt A):152-9.
Ciechanowski P, Chaytor N, Miller J, Fraser R, Russo J, Unutzer J, et al. PEARLS depression treatment for individuals with epilepsy: a randomized controlled trial. Epilepsy Behav. 2010;19:225-31.
Chaytor N, Ciechanowski P, Miller JW, Fraser R, Russo J, Unutzer J, et al. Long-term outcomes from the PEARLS randomized trial for the treatment of depression in patients with epilepsy. Epilepsy Behav. 2011;20:545-9.
Etemadifar S, Heidari M, Jivad N, Masoudi R. Effects of family-centered empowerment intervention on stress, anxiety, and depression among family caregivers of patients with epilepsy. Epilepsy Behav. 2018;88:106-12.
Fraser RT, Johnson EK, Lashley S, Barber J, Chaytor N, Miller JW, et al. PACES in epilepsy: results of a self-management randomized controlled trial. Epilepsia. 2015;56(8):1264-74.
Gandy M, Sharpe L, Nicholson Perry K, Thayer Z, Miller L, Boserio J, et al. Cognitive behaviour therapy to improve mood in people with epilepsy: a randomised controlled trial. Cogn Behav Ther. 2014;43(2):153-66.
Novakova B, Harris PR, Rawlings GH, Reuber M. Coping with stress: a pilot study of a self-help stress management intervention for patients with epileptic or psychogenic nonepileptic seizures. Epilepsy Behav. 2019;94:169-77.
Meyer B, Weiss M, Holtkamp M, Arnold S, Brückner K, Schröder J, et al. Effects of an epilepsy-specific internet intervention (Emyna) on depression: results of the ENCODE randomized controlled trial. Epilepsia. 2019;60(4):656-68.